ABMD - Abiomed acquires preCARDIA a company targeting acute heart failure

Abiomed (ABMD) has acquired preCARDIA Minnesota-based developer of a proprietary catheter and controller targeting patients with acute decompensated heart failure ((ADHF)).preCARDIA system has received Breakthrough Device Designation from the FDA and the enrollment is complete in an FDA early feasibility study ((EFS)) which led to a significant reduction in cardiac filling pressures and rapid diuresis, the company said.“We look forward to advancing preCARDIA’s technology through the regulatory process,” commented Abiomed CEO Michael R. Minogue.preCARDIA system is available for investigational use only, and the anticipated timeline for commercialization will be notified later this fiscal year, the company said in a statement.Despite the underperformance of its share price so far in 2021, William Blair analyst Margaret Kaczor called Abiomed an attractive buy citing its quarterly financials.

For further details see:

Abiomed acquires preCARDIA a company targeting acute heart failure